Personalis launches Next Dx cancer profiling test

By staff writers

January 8, 2020 -- Personalis has announced the launch of its Next Dx comprehensive genomic profiling laboratory-developed test, which is designed for use by oncologists in assessing appropriate treatment options.

The company differentiates the whole exome and transcriptome sequencing product through the comprehensive nature of the profiling, as the platform screens for some 20,000 genes in the tumor exome and transcriptome, in contrast with only a few hundred genes available with some currently marketed products. Personalis noted that the product sheds light on cancer genes and biomarkers that are important for directing treatment with cancer immunotherapies, such as tumor mutational burden (TMB) and microsatellite instability (MSI) status.

Testing is conducted at the company's accredited lab, with analysis by a team of board-certified molecular geneticists and genetic counselors, Personalis said. Reports for ordering clinicians include detailed recommendations for treatment based on genomic profile results and information about clinical trials that may be suitable.

BioMarker Strategies advances immunotherapy test through SBIR grant
BioMarker Strategies has received a $1.5 million Small Business Innovation Research (SBIR) government contract through the U.S. National Cancer Institute...
Merck KGaA, Personalis team up on cancer biomarkers
Merck KGaA will use the ImmunoID NeXT immunogenomics platform of Personalis to develop biomarkers for cancer therapies through a new collaboration.
Promega, Merck team up on Keytruda companion test
Promega and Merck announced a collaboration to develop a polymerase chain reaction companion diagnostic to evaluate microsatellite instability for use...

Copyright © 2020

Last Updated ls 11/5/2021 11:55:19 AM